On April 6, 2026, three companies—SaTRec Initiative, Meritz Financial Group, and Celu Med—submitted corrections and filings related to their business reports for the fiscal year ending December 2025 through DART (Data Analysis, Retrieval and Transfer System), Korea’s electronic disclosure system. All three disclosures were regular filings, demonstrating each company’s commitment to transparent information disclosure.

What is a Business Report Correction Disclosure?

A business report is a crucial document where a company informs the government and investors about its operations over the past year, including revenue, expenses, and future plans. Think of it as similar to a student’s report card at the end of a semester.

Sometimes, after submitting this report, companies discover errors or omissions in the information provided. In such cases, they issue a ‘correction disclosure’ to rectify the mistakes. A content correction involves amending information within the report itself, while an attachment correction means modifying or adding documents attached to the report.

SaTRec Initiative’s Content Correction Disclosure

SaTRec Initiative is one of Korea’s leading aerospace companies specializing in satellite manufacturing. The company submitted a content correction disclosure for its business report for the fiscal year ending December 2025. Content correction means revising portions of the report’s main text.

The aerospace industry is experiencing rapid global growth. Satellites are used for various purposes including communications, weather observation, Earth observation, and military applications. As the commercial space industry expands, the market continues to grow. SaTRec Initiative is gaining attention as a company with small satellite manufacturing technology amid this trend.

Submitting a correction disclosure is not inherently negative. Rather, it demonstrates the company’s effort to provide accurate information. However, investors should verify what content was corrected and whether it affects the company’s financial condition or business outlook.

Meritz Financial Group’s Attachment Correction Disclosure

Meritz Financial Group is a comprehensive financial conglomerate providing various financial services including securities, insurance, and savings banks. The company submitted an attachment correction disclosure for its business report for the fiscal year ending December 2025. Attachment correction refers to modifying or adding financial statements, audit reports, or other supporting documents attached to the report.

Financial holding companies have particularly complex business reports because they oversee multiple financial subsidiaries. They must consolidate financial information from each subsidiary, prepare consolidated financial statements, and comply with various financial regulations. This complexity increases the likelihood of omissions or errors in attached documents.

Meritz Financial Group has pursued aggressive growth strategies in recent years. Meritz Securities maintains a top position in Korea’s securities industry, while Meritz Fire & Marine Insurance shows steady growth in the property insurance market. Accurate financial disclosure is crucial for maintaining investor confidence during this growth phase.

Celu Med’s Business Report Submission

Celu Med is a biotechnology company developing stem cell therapeutics. The company officially submitted its business report for the fiscal year ending December 2025. Unlike the other two companies, this was a standard business report submission rather than a correction disclosure.

Business reports from biotech companies have different characteristics compared to manufacturing or service industries. Key information includes drug development progress, clinical trial results, patent status, and research and development spending. For early-stage biotech companies without significant revenue, the R&D pipeline is the core factor determining corporate value.

Stem cell therapeutics are attracting attention as a field opening new possibilities for treating intractable diseases. They offer potential for fundamental treatment of conditions that were difficult to address with conventional drugs. Celu Med’s business report serves as an important resource for confirming the progress of such R&D activities and financial soundness.

The Importance of Regular Disclosures

All three companies’ filings are classified as ‘regular disclosures.’ Regular disclosures are mandatory filings that companies must submit at designated times, including annual business reports, semi-annual reports, and quarterly reports.

Regular disclosures serve as an institutional mechanism allowing investors to periodically monitor corporate management status. Just as regular health checkups are necessary to understand one’s health condition, regular disclosures enable verification of a company’s ‘financial health.’

Business reports are considered the most important regular disclosures as they comprehensively cover a full year’s management performance. They include not only financial information such as revenue, operating profit, and net income, but also details about major businesses, management status, changes in major shareholder stakes, and risk factors.

Key Points for Investors

There are three main aspects investors should focus on in these disclosures.

First, the correction details for SaTRec Initiative and Meritz Financial Group. Investors should verify which items were corrected, whether the corrections affect key financial statement figures, and if there are changes in business outlook or risk factors. Comparing original and corrected reports in the DART system reveals specific changes.

Second, analysis considering each company’s industry characteristics is necessary. SaTRec Initiative operates in aerospace, Meritz Financial Group in finance, and Celu Med in biotechnology, with different key indicators for each industry. Critical factors include order backlog and technology development for aerospace companies, asset soundness and profitability indicators for financial companies, and pipeline progress and cash reserves for biotech companies.

Third, performance analysis reflecting the 2025 business environment. The year 2025 saw continued global economic uncertainty. Business reports reveal how interest rate fluctuations, exchange rate changes, and industry-specific regulatory environments affected each company’s performance.

How the Disclosure System Protects Investors

Korea’s electronic disclosure system is a crucial mechanism for protecting investors. All listed companies must disclose important management information through DART, and failure to comply can result in fines or sanctions.

The correction disclosure system particularly provides companies an opportunity to rectify incorrect information while compelling them to provide accurate information to investors. If a company intentionally conceals important information or provides false information, it can be punished for violating the Financial Investment Services and Capital Markets Act.

For investors, developing a habit of regularly checking DART disclosures is important. While stock prices rise and fall for various reasons, they are fundamentally based on corporate performance and outlook. If investors can directly verify and analyze this information through disclosures, they can make investment decisions based on facts rather than rumors or speculation.

Future Outlook for the Three Companies

The aerospace industry, where SaTRec Initiative operates, is a field expected to grow globally. Government space development competition is intensifying worldwide, and private companies are actively entering businesses like satellite communications and Earth observation. In Korea, the government is fostering the aerospace industry as a future growth engine, increasing interest in related companies.

Meritz Financial Group is actively responding to changes in the financial industry. The environment surrounding finance is rapidly changing, including the spread of digital finance, interest rate environment shifts, and new financial regulations. How well the company leverages synergies as a comprehensive financial group will determine its future competitiveness.

The biotechnology industry, where Celu Med operates, is a field with simultaneously high risk and high return potential. Drug development requires long timeframes and substantial costs, but success can generate enormous profits. Stem cell therapeutics particularly offer new possibilities for diseases difficult to treat with conventional methods, earning recognition as a field with significant long-term growth potential.

Advice for Becoming a Wise Investor

Reading disclosures may initially seem difficult due to technical terminology and extensive content. However, with consistent reading, you become familiar and learn to identify important sections.

For beginner investors, we recommend starting with the ‘Summary Financial Information’ and ‘Business Description’ sections of business reports. Reading just these two sections provides a general understanding of what business the company conducts and its performance. As you become comfortable, you can explore more specialized sections like ‘Financial Statement Notes’ or ‘Risk Management.’

Most importantly, develop the ability to interpret disclosures’ meaning and apply them to investment decisions, beyond simply reading them. Different investors can reach different conclusions from the same disclosure. This is both the appeal and difficulty of investing.

The disclosures submitted by these three companies are important resources for verifying each company’s 2025 management performance. Investors should directly review the disclosure content on DART and utilize it according to their investment strategies.